A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of...
A Nevada jury awards $14M to a colonoscopy patient who blames his hepatitis on reusable vials of Propofol, marking the third verdict against Baxter International (BAX -1.2%) and Teva Pharmaceuticals (TEVA +0.7%) over an outbreak in the state tied to use of the drug. An attorney for Teva passes off blame to doctors: "It’s not a vial problem... it’s a practice problem."
From other sites
at Zacks.com (Mar 27, 2015)
at Zacks.com (Mar 17, 2015)
at Zacks.com (Mar 9, 2015)
at Nasdaq.com (Mar 6, 2015)
at Nasdaq.com (Feb 2, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs